William P. Donnelly is a seasoned biotechnology executive with over three decades of experience in the life sciences industry, specializing in strategic leadership, corporate development, and commercialization of innovative technologies. His career began in investment banking at Alex. Brown & Sons, where he focused on healthcare mergers and acquisitions, before transitioning to operational roles in biotech. Donnelly held key positions at Genzyme Corporation, including Vice President of Business Development, contributing to its growth into a global leader in rare disease therapies before its acquisition by Sanofi. Notable achievements include his tenure as Chairman and Chief Executive Officer of Dyax Corp., where he spearheaded the development and approval of Kalbitor for hereditary angioedema and orchestrated its $5.9 billion acquisition by Shire in 2016—one of the largest biotech deals of that year. Donnelly has also served on the boards of directors for numerous public and private companies, including Alnylam Pharmaceuticals, Acceleron Pharma, and bluebird bio, providing governance and strategic guidance that drove significant value creation and clinical advancements. As Former Executive Chair of Quanterix Corporation, Donnelly joined the board in 2019 and assumed the role of Executive Chair in 2020, playing a pivotal role in the company's transition to profitability and expansion of its Simoa® ultrasensitive protein detection platform. Under his leadership, Quanterix advanced key partnerships, enhanced its commercial infrastructure, and positioned the company as a leader in precision neurology and oncology diagnostics, culminating in strong revenue growth and market leadership before he stepped down from the role in 2023.